Adolore BioTherapeutics to Present at Virtual Investor Pitch

June 10, 2024 - Adolore BioTherapeutics, a pioneering biotechnology company dedicated to the development of innovative, opioid-free gene therapy treatments for chronic pain, is set to make a significant presentation at the upcoming Virtual Investor Pitch Conference. This highly anticipated event will take place on June 17, 2024, at 10:00 AM ET.

The highlight of the presentation will feature Roelof Rongen, the CEO of Adolore, delivering a concise "elevator pitch" that will outline the key milestones that the company aims to achieve in the near future. In addition to the presentation, there will be a live interactive session where investors and attendees can pose questions to the company representatives. Adolore has committed to addressing as many inquiries as time permits during this live segment.

For those interested in viewing the presentation but unable to attend the live event, a live video webcast will be made available on the event's official website, virtualinvestorco.com. Furthermore, a replay of the webcast will be accessible approximately two hours after the conclusion of the live presentation and will remain available for a period of 90 days.

About Adolore BioTherapeutics

Adolore BioTherapeutics, Inc. is at the forefront of biotechnological innovation, specializing in the development of advanced therapies aimed at treating chronic pain and other conditions affecting the nervous system. The company's flagship programs center around long-duration, locally acting gene therapies that serve as Disease Modifying Anti-Pain Therapies (DMAPs). These therapies are meticulously designed to offer effective treatments for various types of chronic pain without relying on opioids.

Adolore's leading CA8* gene therapy initiatives are currently in the preclinical development stage, targeting patients suffering from erythromelalgia and chronic knee osteoarthritis pain. Erythromelalgia is a rare, hereditary chronic pain condition for which there is currently no approved treatment, categorizing it as an orphan drug disease. On the other hand, chronic knee osteoarthritis pain affects a significant patient population, many of whom are often treated with opioids due to the absence of viable alternative treatments. This reliance contributes to the ongoing opioid crisis, underscoring the urgent need for new therapeutic solutions.

Adolore's innovative approach seeks to address these critical gaps by providing long-lasting, opioid-free therapeutic options, thereby potentially transforming the treatment landscape for chronic pain sufferers.

Webcast Information

- Event: Virtual Investor Pitch Conference
- Date: June 17, 2024
- Time: 10:00 AM ET
- Webcast Access: Available on virtualinvestorco.com
- Webcast Replay: Accessible two hours post-event and available for 90 days

By participating in this event, Adolore BioTherapeutics hopes to engage with a broader investor audience, share its groundbreaking advancements, and highlight its commitment to addressing the opioid crisis through innovative gene therapy solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!